Pharming Group NV

The US FDA has approved Pharming Group's Joenja, also known as leniolisib, for children between the ages of four and 11 with a rare genetic immune system disorder. The treatment was previously approved in 2023 for individuals 12 years and older with activated phosphoinositide 3-kinase delta syndrome, or APDS. The approval was based on safety and pharmacokinetic data from a single-arm, open-label study. Individuals with APDS suffer from recurrent infections, especially in the sinuses, ears, and respiratory tract, and also develop enlarged lymph nodes, tonsils, and spleen.

Pharming Group announced the commercial launch of Joenja (leniolisib) in Japan for adults and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in the NHI price list. Joenja, an oral PI3Kd inhibitor, was approved based on results from a randomized, placebo-controlled Phase III trial that met its coprimary endpoints, showing statistically significant improvements in immune function. Pharming CFO Leverne Marsh called the launch a major milestone in expanding access to Joenja globally, particularly for younger patients in Japan who previously had no approved treatment options. The approval was granted earlier this year by Japan's Ministry of Health, Labour and Welfare, with OrphanPacific, Inc. serving as the local marketing authorization holder and distributor partner. Pharming shares closed Wednesday at $11.83, down 3.27%, and were up 3.13% at $12.20 in overnight trading.